WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 319763
CAS#: 14087-31-1
Description: Gaxilose, also known as 4-Galactosylxylose, a synthetic disaccharide and a substrate of intestinal lactase. Gaxilose is used in a new noninvasive diagnostic test based on urine or serum measurement of D-xylose after lactase cleavage of orally administered 4-galactosylxylose (gaxilose). Gaxilose is hydrolyzed into galactose and xylose in vivo. Galactose is converted into glucose in the liver and xylose is absorbed from a passive way and partially metabolized endogenously (50%). The rest appears in blood and it is excreted finally through urine. The amount of xylose in urine is proportional to the activity of intestinal lactase. This represents a direct measure of hypo or normo lactasia.
MedKoo Cat#: 319763
Name: Gaxilose
CAS#: 14087-31-1
Chemical Formula: C11H20O10
Exact Mass: 312.1056
Molecular Weight: 312.271
Elemental Analysis: C, 42.31; H, 6.46; O, 51.23
Synonym: 4-O-Galactosyl-D-xylose; 4-O-Galactosylxylose; 4-Galactosylxylose; Gaxilose
IUPAC/Chemical Name: (3R,4R,5R)-5-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2,3,4-triol
InChi Key: VCTBNHVCBSUQPG-NCRZSTDJSA-N
InChi Code: InChI=1S/C11H20O10/c12-1-3-5(13)7(15)9(17)11(20-3)21-4-2-19-10(18)8(16)6(4)14/h3-18H,1-2H2/t3-,4-,5+,6+,7+,8-,9-,10?,11+/m1/s1
SMILES Code: OC1[C@@H]([C@H]([C@@H](CO1)O[C@H]2[C@@H]([C@H]([C@H]([C@@H](CO)O2)O)O)O)O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 312.271 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Domínguez Jiménez JL, Fernández Suárez A, Muñoz Colmenero AÚ, Fatela Cantillo D, López Pelayo I. Primary hypolactasia diagnosis: Comparison between the gaxilose test, shortened lactose tolerance test, and clinical parameters corresponding to the C/T-13910 polymorphism. Clin Nutr. 2016 Jan 20. pii: S0261-5614(16)00008-X. doi: 10.1016/j.clnu.2016.01.006. [Epub ahead of print] PubMed PMID: 26847948.
2: Hermida C, Martínez-Costa OH, Corrales G, Teruel C, Sánchez V, Sánchez JJ, Sarrión D, Ariza MJ, Codoceo R, Calvo I, Fernández-Mayoralas A, Aragón JJ. Improvement and validation of d-xylose determination in urine and serum as a new tool for the noninvasive evaluation of lactase activity in humans. J Clin Lab Anal. 2014 Nov;28(6):478-86. doi: 10.1002/jcla.21713. Epub 2014 Mar 22. PubMed PMID: 24659338.
3: Aragón JJ, Hermida C, Martínez-Costa OH, Sánchez V, Martín I, Sánchez JJ, Codoceo R, Cano JM, Cano A, Crespo L, Torres Y, García FJ, Fernández-Mayoralas A, Solera J, Martínez P. Noninvasive diagnosis of hypolactasia with 4-Galactosylxylose (Gaxilose): a multicentre, open-label, phase IIB-III nonrandomized trial. J Clin Gastroenterol. 2014 Jan;48(1):29-36. doi: 10.1097/MCG.0b013e318297fb10. PubMed PMID: 23722657.
4: Hermida C, Guerra P, Martínez-Costa OH, Sánchez V, Sánchez JJ, Solera J, Fernández-Mayoralas A, Codoceo R, Frías J, Aragón JJ. Phase I and phase IB clinical trials for the noninvasive evaluation of intestinal lactase with 4-galactosylxylose (gaxilose). J Clin Gastroenterol. 2013 Jul;47(6):501-8. doi: 10.1097/MCG.0b013e318272f507. PubMed PMID: 23328304.
5: Hermida C, Corrales G, Martínez-Costa OH, Fernández-Mayoralas A, Aragón JJ. Noninvasive evaluation of intestinal lactase with 4-galactosylxylose: comparison with 3- and 2-galactosylxylose and optimization of the method in rats. Clin Chem. 2006 Feb;52(2):270-7. Epub 2005 Dec 29. PubMed PMID: 16384892.
6: Aragón JJ, Fernández-Mayoralas A, Jiménez-Barbero J, Martín-Lomas M, Rivera-Sagredo A, Villanueva D. Evaluation of rat intestinal lactase in vivo with 4-galactosylxylose. Clin Chim Acta. 1992 Sep 30;210(3):221-6. PubMed PMID: 1468143.
7: Rivera-Sagredo A, Fernández-Mayoralas A, Jiménez-Barbero J, Martín-Lomas M, Villanueva D, Aragón JJ. 4-O-beta-D-galactopyranosyl-D-xylose: a new synthesis and application to the evaluation of intestinal lactase. Carbohydr Res. 1992 Apr 10;228(1):129-35. PubMed PMID: 1516083.
8: Rio S, Beau JM, Jacquinet JC. Synthesis of glycopeptides from the carbohydrate-protein linkage region of proteoglycans. Carbohydr Res. 1991 Oct 14;219:71-90. PubMed PMID: 1804538.
